MAP2K7 and lung cancer: Similarly, MEK inhibition is being assessed clinically to enhance the efficacy of EGFR inhibitor therapy in lung cancer, as both EGFR-intrinsic and extrinsic mechanisms of EGFR inhibitor resistance led to the activation of MEK/ERK signaling [89, 90].